yemenjmedYemen Journal of MedicinecoVolume 1 Issue 1MultidisciplinaryEnglishJanuary - June 2022NNY20250327ArticleFrequency of statin-induced liver injury: A secondary analysis of previous hospital-based studyEnglishY2730Abdel-Monem BadawiYousifEnglishNEbtihal AbdelmoneimHassanEnglishY10.32677/yjm.v1i1.3286Background:Although statins are considered safe, they do have side effects with a wide range of hepatic adverse effects. The present study aims to estimate the frequency of liver injury in patients treated with various statins and to describe their clinical characteristics and outcomes. Materials and Methods: We carried out a secondary post hoc analysis of collected data from our previous study entitled “Frequency of Rhabdomyolysis in Patients Treated with Statins in Hamad General Hospital, Qatar.” Results: We identified 10 cases (1.0%) of statin-induced liver injury during the study period. Their mean age was 62±10.09 years, with 6 (60%) males and 4 (40%) females. Of the 10 patients, six patients received rosuvastatin, two patients received atorvastatin, and other two cases received simvastatin. The mean duration between the initiation of statin and the development of liver injury (latency period) was 20.40±6.91 months. Five of our patients were asymptomatic, and liver injury was discovered incidentally during routine testing of the patients during routine follow-up, while four patients developed painless jaundice and one developed muscle pain attributed to rhabdomyolysis. Statins were stopped in all patients. Nine of them were managed on an outpatient basis, while one patient with rhabdomyolysis was admitted. In all patients, other statins were reintroduced after a mean time of 7.4±3 months without recurrence of liver injury. No mortality has been reported. Conclusion: Our study demonstrated that statin-induced liver injury is a rare clinical entity that occurs regardless of the dose and type of statin, with rosuvastatin being the most causative drug. Statin-induced liver injury was asymptomatic and was discovered incidentally in 50% of our cases during routine testing, underscoring the importance of routine follow-up of liver function tests in asymptomatic patients.EnglishAtorvastatin, Rosuvastatin, Simvastatin, Statin-induced liver injuryhttps://yemenjmed.com/admin/abstract?id=18References16191. Russo MW, Hoofnagle JH, Gu J, et al. Spectrum of statin hepatotoxicity: Experience of the drug-induced liver injury network. Hepatology 2014;60:679-86.2. Clarke AT, Mills PR. Atorvastatin associated liver disease. Dig Liver Dis 2006;38:772-7.3. Jose J. Statins and its hepatic effects: Newer data, implications, and changing recommendations. J Pharm Bioallied Sci 2016;8:23-8.4. Chalasani N. Statins and hepatotoxicity: Focus on patients with fatty liver. Hepatology 2005;41:690-5.5. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: A systematic overview of randomized clinical trials. Circulation 2006;114:2788-97.6. Chitturi S, George J. Hepatotoxicity of commonly used drugs: Nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis 2002;22:169-83.7. Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011;55:683-91.8. Perdices EV, Medina-Cand;aacute;liz I, Hernando S, et al. Hepatotoxicity associated with statin use: Analysis of the cases included in the Spanish hepatotoxicity registry. Rev Esp Enferm Dig 2014;106:246-54.9. Yousif AB, Hassan EA, Ahmed MU, et al. Frequency of rhabdomyolysis in patients treated with statins in hamad general hospital, Qatar. Libyan J Medand;nbsp;Sci 2021;5:75-8.10. National Institute for Health and Care Excellence. Cardiovascular Disease: Risk Assessment and Reduction, Including Lipid Modification; 2016. Available from: https://www.nice.org.uk/guidance/cg181 [Last accessed on 2022 Jan 01].11. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. A report of the American college of cardiology/American heart association task force on practice guidelines. Circulation 2014;129:1-45.12. Chang CY, Schiano TD. Review article: Drug hepatotoxicity. Aliment Pharmacol Ther 2007;25:1135-51.13. Cohen DE, Anania FA, Chalasani N, et al. An assessment of statin safety by hepatologists. Am J Cardiol 2006;97:77-81.14. Bjornsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing. J Hepatol 2012;56:374-80.15. Bjand;ouml;rnsson ES. Hepatotoxicity of statins and other lipid-lowering agents. Liver Int 2017;37:173-8.16. Tolosa L, Carmona A, Castell JV, et al. High-content screening of druginduced mitochondrial impairment in hepatic cells: Effects of statins. Arch Toxicol 2015;89:1847-60.17. Pelli N, Setti M, Ceppa P, et al. Autoimmune hepatitis revealed by atorvastatin. Eur J Gastroenterol Hepatol 2003;15:921-4.18. Halegoua-De Marzio VJ. Hepatotoxicity of cardiovascular and antidiabetic drugs. In: Kaplowitz N, DeLeve L, editor. Drug-Induced Liver Disease. 3rd ed. United States: Academic Press; 2013. p. 519-40.19. Liu Y, Cheng Z, Ding L, et al. Atorvastatin-induced acute elevation of hepatic enzymes and the absence of cross-toxicity of pravastatin. Int J Clin Pharmacol Ther 2010;48:798-802.